Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of TG103 injection in overweight or obese adults with type 2 diabetes mellitus
ChiCTR2100051312Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of GX-G6 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Glycated hemoglobin. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100051312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051312.